Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: An intravaginal contraceptive device has a biocompatible support structure constructed and configured to be inserted into a mammal's vagina without substantially blocking the cervix, coated by a multilayer coating having one or more biodegradable polymers. The multilayer coating can be constructed and formed of materials such that the multilayer coating dissolves over a period of at least three days, wherein each layer of the multilayer coating includes a spermicidal and/or spermiostatic composition and is constructed and formed to dissolve at varying times. Additionally, the multilayer coating is preferably constructed and formed of materials effective to provide a sustained release of a spermicidally or spermiostatically effective amount of the composition for at least three days.

Abstract: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula I Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula I as well as methods of making and using them.

Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.

Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.

Abstract: The present invention relates to a method of inhibiting HIV-1 activity in a cell. This method involves providing a cell infected with HIV-1 and contacting the cell with a compound of Formula I where R1 is —CH3, ?O, —OH, —OCH3, or —OC(O)CH3, and R2 is —H, —CH3, —CHO, —CH2OH, —CH2OCH3, —CH2OC(O)CH3, —COCH3, or —COOH, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell. A method of treating HIV-1 infection in a subject is also disclosed. This method involves administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection.

Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine. Antibodies to LH-R are useful in regulating steroid hormone production. Nucleic acid sequences encoding polypeptides with LH receptor activity were obtained and sequenced.